[BCG therapy of superficial tumors of the bladder].
Superficial bladder tumor defined as pTa, pT1 and pTis stage is one of the most common cancer disease in the world. Intravesical BCGtherapy represents the best treatment when combined with transurethral resection to prevent tumor recurrence or progression and to lengthen the interval between recurrence. The toxicity is quite important but can be reduced by using the good procedure. Local or general immunostimulation is likely to be the exact mechanism of action but more data are needed.
Prapotnich
D
D
Institut mutualiste Montsouris, Paris.
D000283:Administration, Intravesical; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001500:BCG Vaccine / Q000009:adverse effects / Q000627:therapeutic use*; D019496:Cancer Vaccines / Q000009:adverse effects / Q000627:therapeutic use*; D002295:Carcinoma, Transitional Cell / Q000473:pathology / Q000628:therapy*; D000075202:Contraindications; D006801:Humans; D009367:Neoplasm Staging; D011379:Prognosis; D001749:Urinary Bladder Neoplasms / Q000473:pathology / Q000628:therapy*
D000970:Antineoplastic Agents; D001500:BCG Vaccine; D019496:Cancer Vaccines